QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Persistent Asthma
Conditions
Persistent Asthma
Trial Timeline
Nov 1, 2010 → Sep 1, 2011
NCT ID
NCT01253603About QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days is a phase 2 stage product being developed by Novartis for Persistent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01253603. Target conditions include Persistent Asthma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01253603 | Phase 2 | Completed |
Competing Products
20 competing products in Persistent Asthma